Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
Neurogene (NGNE) Stock Price & Analysis
421 Followers
NGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.20 - $53.00
Previous Close$33.59
Volume51.19K
Average Volume (3M)139.98K
Market Cap
$436.01M
Enterprise Value$364.99M
Total Cash (Recent Filing)$82.06M
Total Debt (Recent Filing)$11.04M
Price to Earnings (P/E)-12.7
Beta0.92
Next Earnings
May 10, 2024EPS Estimate
-$1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.65
Shares Outstanding12,980,289
10 Day Avg. Volume56,821
30 Day Avg. Volume139,977
Standard Deviation0.29
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.68
Forecast
1Y Price Target
$46.67Price Target Upside38.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Neurogene News
PremiumCompany Announcements
Neurogene Inc. Optimistic on NGN-401 Trial Progress
PremiumCompany Announcements
Neurogene Reveals Encouraging Gene Therapy Trial Results
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressPresented safety data showed no signs/symptoms indicative of MeCP2 overexpression, suggesting NGNE's treatment may be safe.
Financial StabilityNGNE has a robust cash position expected to fund operations for an extended period, which highlights the company's financial stability.
Regulatory ApprovalNGNE received clearance from the Australian Human Research Ethics Committee (HREC) to expand the ongoing Rett development program.
Bears Say
Competitive LandscapeCompetitor TSHA-102 has shown modest benefits and variable expression, which may be seen as a lower clinical benchmark for NGN-401 to beat.
Financial PerformanceFinancial expenses for R&D and SG&A were above estimates, indicating higher than expected costs.
Stock ValuationPrice target lowered to $51 due to an increase in potentially dilutive securities.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $12.20 and its highest was $53.00 in the past 12 months.
What is Neurogene’s market cap?
Currently, no data Available
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is May 10, 2024 which is 6 days ago.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Mar 18, 2024. The company reported $2.93 earnings per share for the quarter, beating the consensus estimate of -$1.173 by $4.103.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -$1.03.
How many shares outstanding does Neurogene have?
Neurogene has 12,980,289 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of $2.93 in its last earnings report, beating expectations of -$1.173. Following the earnings report the stock price went down -2.138%.
Which hedge fund is a major shareholder of Neurogene?
Among the largest hedge funds holding Neurogene’s share is Baker Bros Advisors LP. It holds Neurogene’s shares valued at 23M.
---
Neurogene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.67 (38.94% Upside)
$46.67 (38.94% Upside)
Blogger Sentiment
Bullish
NGNE Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 11.6%
Last 30 Days ▼ 11.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.16%
12-Months-Change
Fundamentals
Return on Equity
-30.96%
Trailing 12-Months
Asset Growth
98.41%
Trailing 12-Months
Company Description
Neurogene
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
---
NGNE Stock 12 Month Forecast
Average Price Target
$46.67
▲(38.94% Upside)
Technical Analysis
Best Analysts Covering NGNE
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+9.25%
assigned a buy rating 4 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +9.25% per trade.
---